Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 10/20 | 0.53 |
| ▸ | AKR1C2 | P52895 | 10/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12264144 | 0.93 | SMN1; SMN2 (0.51) | SMN1; SMN2AKR1C3AKR1C2NPC1RAB9A | |
| SCHEMBL12240321 | 0.88 | AKR1C3 (0.50) | SMN1; SMN2AKR1C3AKR1C2NPC1RAB9A | |
| SCHEMBL823582 | 0.85 | SMN1; SMN2 (0.57) | SMN1; SMN2AKR1C3AKR1C2KDM4EPOLB | |
| SCHEMBL11175864 | 0.85 | ALDH1A1 (0.62) | AKR1C3AKR1C2NPC1RAB9AKDM4E | |
| SCHEMBL9710209 | 0.84 | KDM4E (0.49) | SMN1; SMN2NPC1RAB9AKDM4EPOLB | |
| SCHEMBL6225082 | 0.84 | NPC1 (0.49) | SMN1; SMN2AKR1C3AKR1C2NPC1RAB9A | |
| SCHEMBL14273079 | 0.82 | CYP1A2 (0.56) | SMN1; SMN2AKR1C3AKR1C2NPC1RAB9A | |
| SCHEMBL383820 | 0.80 | ALDH1A1 (0.66) | SMN1; SMN2AKR1C3AKR1C2NPC1RAB9A | |
| SCHEMBL30407941 | 0.79 | EDNRA (0.52) | SMN1; SMN2AKR1C3AKR1C2NPC1KDM4E | |
| SCHEMBL11758498 | 0.79 | AKR1C3 (0.44) | SMN1; SMN2AKR1C3AKR1C2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2200439-B1 | HDAC INHIBITORS | LIXTE BIOTECHNOLOGY INC (US) | 2017-03-22 | — | — | EP | disclosed |
| US-8143445-B2 | HDAC inhibitors | LIXTE BIOTECHNOLOGY, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| EP-2200439-A1 | HDAC INHIBITORS | Lixte Biotechnology, Inc. (US) | 2010-06-30 | — | — | EP | disclosed |
| US-20090143445-A1 | HDAC Inhibitors | JOHN P. WHITE, ESQ | 2009-06-04 | — | — | US | disclosed |
| WO-2009045440-A1 | HDAC INHIBITORS | LIXTE BIOTECHNOLOGY HOLDINGS, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
| EP-0775110-B1 | ARYLTHIO COMPOUNDS AS ANTIBACTERIAL AND ANTIVIRAL AGENTS | WARNER LAMBERT CO (US) | 2005-10-05 | — | — | EP | disclosed |
| EP-0828488-B1 | ISOTHIAZOLONES | WARNER LAMBERT CO (US) | 2003-02-12 | — | — | EP | disclosed |
| US-6133270-A | Isothiazolones and pharmaceutical formulations | WARNER-LAMBERT COMPANY (US) | 2000-10-17 | — | — | US | disclosed |
| US-6001863-A | USEFUL AS ANTIVIRAL, ANTIINFLAMMATORY AND ANTIATHEROSCLEROSIS AGENT; ADMINISTERING TO THE PATIENT IN NEED OF ZINC EJECTION FROM NUCLEOCAPSID PROTEIN | WARNER-LAMBERT COMPANY (US) | 1999-12-14 | — | — | US | disclosed |
| US-5929114-A | ADMINISTERING ANTIVIRAL COMPOUND WHICH EXTRUDES ZINC FROM NUCLEOCAPSID PROTEIN OF HUMAN IMMUNODEFICIENCY VIRUS | WARNER-LAMBERT COMPANY (US) | 1999-07-27 | — | — | US | disclosed |
| US-5889034-A | ANTIINFLAMMATORY AGENT; ANTIATHEROSCLEROSIS AGENT; VIRICIDES | WARNER-LAMBERT COMPANY (US) | 1999-03-30 | — | — | US | disclosed |
| US-5734081-A | Arylthio compounds | WARNER-LAMBERT COMPANY (US) | 1998-03-31 | — | — | US | disclosed |
| US-5733921-A | ANTIRETROVIRAL AGENTS; ANTIINFLAMMATORY AGENTS; ANTIATHEROSCLEROSIS | WARNER-LAMBERT COMPANY (US) | 1998-03-31 | — | — | US | disclosed |
| US-5668291-A | THIOSUBSTITUTED PYRIDINES, TREATMENT OF AIDS AND HIV | WARNER-LAMBERT COMPANY (US) | 1997-09-16 | — | — | US | disclosed |
| US-5668162-A | Isothiazolones lower plasma levels of lipoprotein(a) | WARNER-LAMBERT COMPANY | 1997-09-16 | — | — | US | disclosed |
| US-5620997-A | VIRICIDES, ANTIINFLAMMATORY AGENTS, ANTIATHEROSCLEROTIC AGENT | WARNER-LAMBERT COMPANY (US) | 1997-04-15 | — | — | US | disclosed |
| WO-1992021668-A1 | BENZOTHIAZEPINONES AND THEIR USE AS ANTICONVULSANTS | THE BOOTS COMPANY PLC (GB) | 1992-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143445-A1 | HDAC Inhibitors | HDAC3, HDAC7, HDAC4 | SMN1; SMN2 2311/4885AKR1C3 221/4885AKR1C2 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.